What are Amgen's main products contributing to its revenue?

Amgen's primary revenue drivers are EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim). The report also highlights the recent US launch of Aranesp™ (darbepoetin alfa) in October 2001, which is expected to contribute to future growth in the anemia franchise.

How did Amgen's profitability change compared to the previous year?

For the nine months ended September 30, 2001, Amgen reported a net income of $956.7 million, an increase from $927.7 million in the same period of 2000. Diluted earnings per share also saw a slight improvement, rising to $0.88 from $0.86.

What is Amgen's outlook regarding future product sales and earnings?

Amgen expects continued growth. Combined EPOGEN® and Aranesp™ sales are anticipated to grow at a low-double digit rate for 2001 over 2000 EPOGEN® sales. NEUPOGEN® sales growth is projected to be in the high-single digits for 2001. Overall, the company anticipates low-double digit growth in total product sales and earnings per share for 2001, excluding non-recurring items.

What is the status of the collaboration agreement with Praecis Pharmaceutical?

Amgen and Praecis announced they are ending their agreement to jointly develop and commercialize Plenaxis™ (abarelix depot). Amgen is transitioning responsibilities to Praecis and is negotiating financial and other termination matters. The company noted it's possible it may incur a loss from this termination but cannot estimate the amount at this time.

AMGN 10-Q Quarterly Report Q3 FY2001 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported solid financial results for the nine months ended September 30, 2001, showcasing growth in product sales and net income compared to the prior year period. Total revenues increased to $2.89 billion, driven by strong performance in its key products, EPOGEN® and NEUPOGEN®. Net income reached $956.7 million, a notable increase from $927.7 million in the same period of 2000. The company also highlighted its progress in strategic initiatives, including the US launch of Aranesp™ in October 2001, a significant development for its anemia franchise. While operating expenses saw an increase, largely due to investments in research and development and selling, general, and administrative activities to support existing products and new launches, profitability remained robust. Amgen maintained a strong liquidity position with substantial cash and marketable securities, supported by operating cash flows and available debt financing, indicating continued financial stability.

Key Highlights

1Total revenues for the nine months ended September 30, 2001, rose to $2.89 billion, an increase of 8% from $2.68 billion in the prior year period.
2Net income for the nine months ended September 30, 2001, was $956.7 million, up from $927.7 million in the same period of 2000, resulting in diluted EPS of $0.88 compared to $0.86.
3Product sales for the nine months increased by 8% to $2.54 billion, driven by EPOGEN®/Aranesp™ and NEUPOGEN® sales growth.
4The company received US approval and launched Aranesp™ in October 2001 for anemia associated with chronic renal failure, marking a key expansion of its anemia franchise.
5Research and Development (R&D) expenses increased by 6% to $632.4 million for the nine months, reflecting continued investment in product development.
6Selling, General, and Administrative (SG&A) expenses increased by 12% to $644.5 million for the nine months, supporting existing products and new launches.
7Amgen maintained a strong balance sheet with total assets of $6.05 billion as of September 30, 2001, and a significant cash and marketable securities balance of $2.43 billion.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions